TD Private Client Wealth LLC lifted its holdings in shares of HCA Healthcare, Inc. (NYSE:HCA - Free Report) by 10.2% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 7,464 shares of the company's stock after purchasing an additional 690 shares during the quarter. TD Private Client Wealth LLC's holdings in HCA Healthcare were worth $2,859,000 at the end of the most recent quarter.
Several other hedge funds have also recently bought and sold shares of the stock. Price T Rowe Associates Inc. MD increased its position in shares of HCA Healthcare by 83.4% during the first quarter. Price T Rowe Associates Inc. MD now owns 2,399,372 shares of the company's stock worth $829,104,000 after acquiring an additional 1,091,416 shares in the last quarter. Goldman Sachs Group Inc. increased its holdings in HCA Healthcare by 49.1% during the 1st quarter. Goldman Sachs Group Inc. now owns 1,781,459 shares of the company's stock worth $615,583,000 after purchasing an additional 587,036 shares in the last quarter. GAMMA Investing LLC boosted its position in shares of HCA Healthcare by 40,527.3% during the first quarter. GAMMA Investing LLC now owns 1,703,907 shares of the company's stock worth $5,887,850,000 after buying an additional 1,699,713 shares during the period. Nuveen LLC acquired a new stake in HCA Healthcare in the 1st quarter valued at approximately $569,217,000. Finally, Pacer Advisors Inc. boosted its position in HCA Healthcare by 6,237.9% during the 1st quarter. Pacer Advisors Inc. now owns 1,350,933 shares of the company's stock worth $466,815,000 after acquiring an additional 1,329,618 shares during the last quarter. 62.73% of the stock is currently owned by institutional investors and hedge funds.
Insider Buying and Selling at HCA Healthcare
In related news, EVP Michael S. Cuffe sold 3,836 shares of the firm's stock in a transaction dated Monday, September 8th. The stock was sold at an average price of $418.84, for a total value of $1,606,670.24. Following the sale, the executive vice president directly owned 31,503 shares of the company's stock, valued at $13,194,716.52. This trade represents a 10.85% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. 1.30% of the stock is currently owned by corporate insiders.
HCA Healthcare Price Performance
NYSE:HCA opened at $416.68 on Thursday. The firm has a market cap of $97.50 billion, a price-to-earnings ratio of 17.51, a P/E/G ratio of 1.29 and a beta of 1.41. The firm's 50-day simple moving average is $387.59 and its 200 day simple moving average is $367.58. HCA Healthcare, Inc. has a 52 week low of $289.98 and a 52 week high of $420.98. The company has a debt-to-equity ratio of 69.07, a quick ratio of 0.86 and a current ratio of 0.98.
HCA Healthcare (NYSE:HCA - Get Free Report) last announced its quarterly earnings data on Friday, July 25th. The company reported $6.84 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $6.20 by $0.64. HCA Healthcare had a net margin of 8.21% and a negative return on equity of 7,363.11%. The firm had revenue of $18.61 billion for the quarter, compared to the consensus estimate of $18.49 billion. During the same period in the prior year, the company posted $5.50 earnings per share. The business's revenue for the quarter was up 6.4% on a year-over-year basis. HCA Healthcare has set its FY 2025 guidance at 25.500-27.000 EPS. As a group, sell-side analysts predict that HCA Healthcare, Inc. will post 24.98 earnings per share for the current year.
HCA Healthcare Announces Dividend
The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 30th. Stockholders of record on Tuesday, September 16th will be paid a $0.72 dividend. The ex-dividend date is Tuesday, September 16th. This represents a $2.88 annualized dividend and a dividend yield of 0.7%. HCA Healthcare's dividend payout ratio (DPR) is presently 12.11%.
Analyst Ratings Changes
Several research analysts recently commented on the stock. Truist Financial increased their target price on shares of HCA Healthcare from $390.00 to $415.00 and gave the stock a "buy" rating in a report on Wednesday, July 16th. Wells Fargo & Company decreased their price objective on HCA Healthcare from $385.00 to $375.00 and set an "equal weight" rating for the company in a report on Thursday, August 14th. Barclays increased their price target on HCA Healthcare from $390.00 to $445.00 and gave the company an "overweight" rating in a research report on Thursday, September 18th. Cantor Fitzgerald reissued an "overweight" rating and issued a $444.00 price objective on shares of HCA Healthcare in a report on Tuesday, August 26th. Finally, Morgan Stanley reduced their target price on HCA Healthcare from $410.00 to $400.00 and set an "equal weight" rating for the company in a research note on Monday, July 28th. One equities research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and nine have assigned a Hold rating to the stock. According to MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $407.75.
Check Out Our Latest Stock Analysis on HCA Healthcare
HCA Healthcare Company Profile
(
Free Report)
HCA Healthcare, Inc, through its subsidiaries, owns and operates hospitals and related healthcare entities in the United States. It operates general and acute care hospitals that offers medical and surgical services, including inpatient care, intensive care, cardiac care, diagnostic, and emergency services; and outpatient services, such as outpatient surgery, laboratory, radiology, respiratory therapy, cardiology, and physical therapy.
Featured Articles

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider HCA Healthcare, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and HCA Healthcare wasn't on the list.
While HCA Healthcare currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.
Get This Free Report